Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642696 | 0.96 | — | — | |
| SCHEMBL2225649 | 0.93 | HIF1A (0.43) | — | |
| SCHEMBL8200673 | 0.93 | HIF1A (0.43) | — | |
| Water SCHEMBL6572613 | 0.93 | — | — | |
| Hydrochloric Acid SCHEMBL1983463 | 0.93 | — | — | |
| Bromide SCHEMBL5323671 | 0.93 | — | — | |
| SCHEMBL5979256 | 0.93 | HIF1A (0.43) | — | |
| Hydrochloric Acid SCHEMBL9937376 | 0.90 | HIF1A (0.31) | — | |
| Hydrochloric Acid SCHEMBL2447319 | 0.90 | HIF1A (0.31) | — | |
| Bromide SCHEMBL6055853 | 0.90 | HIF1A (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008127078-A1 | ANTI-CANCER AGENT COMPRISING 4-HEXADECANOYL-1,1-DIMETHYL-PIPERAZIN-1-IUM IODIDE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-10-23 | — | — | WO | claimed |
| EP-1537074-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-06-08 | — | — | EP | claimed |
| WO-2004022526-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-03-18 | — | — | WO | claimed |
| EP-4284790-A1 | TARGETED DELIVERY OF 1, 2, 4, 5-TETRAOXANE COMPOUNDS AND THEIR USES | Westlake University (CN) | 2023-12-06 | — | — | EP | disclosed |
| CN-117157281-A | Targeted delivery of 1,2,4, 5-tetraoxacompounds and uses thereof | 西湖大学 | 2023-12-01 | — | — | CN | disclosed |
| US-11773078-B2 | Furin inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20220315556-A1 | FURIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-10-06 | — | — | US | disclosed |
| US-11274092-B2 | Potassium channel inhibitors | ACESION PHARMA APS (DK) | 2022-03-15 | — | — | US | disclosed |
| US-20210188804-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2021-06-24 | — | — | US | disclosed |
| CN-109153667-B | Novel potassium channel inhibitors | 阿塞西翁制药公司 | 2021-04-02 | — | — | CN | disclosed |
| EP-3419973-B1 | NOVEL POTASSIUM CHANNEL INHIBITORS | ACESION PHARMA APS (DK) | 2020-04-08 | — | — | EP | disclosed |
| WO-2017049252-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS | SWITCH BIO, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-2054398-A1 | NEW HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN ATOMS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR TREATMENT OF CANCER | Korea Research Institute of Bioscience and Biotechnology (KR) | 2009-05-06 | — | — | EP | disclosed |
| WO-2008127078-A1 | ANTI-CANCER AGENT COMPRISING 4-HEXADECANOYL-1,1-DIMETHYL-PIPERAZIN-1-IUM IODIDE | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-10-23 | — | — | WO | disclosed |
| EP-1981635-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | Ciba Holding Inc. (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2008018778-A1 | NEW HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN ATOMS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR TREATMENT OF CANCER | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007090461-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA HOLDING INC. (CH) | 2007-08-16 | — | — | WO | disclosed |
| EP-1537074-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022526-A1 | CATHEPSIN CYSTEINE PROTEASE INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 2004-03-18 | — | — | WO | disclosed |
| WO-2000002903-A1 | CS-1 PEPTIDOMIMETICS, COMPOSITIONS AND METHODS OF USING THE SAME | CYTEL CORPORATION (US) | 2000-01-20 | — | — | WO | disclosed |